Proton Rahman
154 Le Marchant Road, A1C 5B8
St. John's, NL, Canada
St. John's, NL, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 201 publications
Distinct gut microbiomic and metabolomic signatures in knee and hip osteoarthritis.
Journal: The Journal of rheumatology
Published: July 01, 2026
FOXO3a Polymorphisms Are Not Associated With Axial Spondyloarthritis or Psoriatic Arthritis Susceptibility in a Canadian Cohort, With Ancestry-Specific Findings.
Journal: International journal of rheumatic diseases
Published: May 01, 2026
Effects of Guselkumab on Structural Damage Progression in Patients with Active Psoriatic Arthritis.
Journal: Advances in therapy
Published: November 20, 2025
Altered gut microbiota and host pathways in obesity-related knee osteoarthritis.
Journal: Clinical and experimental rheumatology
Published: October 24, 2025
Exploring the Genetic Landscape of Psoriatic Arthritis: A Narrative Review of Recent Genomic Studies.
Journal: The Journal of rheumatology
Published: July 21, 2025
Suggestive Association Between Tryptophan-indole Metabolic Pathway and Total Joint Arthroplasty Early Revision for Heterogeneous Failure Modes in Patients With Primary Osteoarthritis: A Meta-analysis of Metabolomics.
Journal: Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews
Published: July 18, 2025
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical Trials.
Journal: JAMA dermatology
Published: July 09, 2025
EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis.
Journal: Annals of the rheumatic diseases
Published: July 04, 2025
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study.
Journal: Annals of the rheumatic diseases
Published: June 02, 2025
Residual Disease Activity and Burden of Disease in Canadian Patients With Axial Spondyloarthritis: Results From a Multiregistry Analysis (UNISON-Axial SpA).
Journal: The Journal of rheumatology
Published: May 07, 2025
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration.
Journal: Advances in therapy
Published: May 05, 2025
Safety of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting.
Journal: Rheumatology and therapy
Published: May 01, 2025
Last Updated: 09/26/2026